Vinpocetine in the treatment of chronic cerebral circulation insufficiency Reprint from: Winpocetyna. Znaczenie w praktyce klinicznej. Biblioteka Medycyny Faktów. Warszawa 2013: 39-43.
Article Sidebar
Published:
Jun 30, 2014
Keywords:
vinpocetine, chronic cerebral circulation insufficiency, neuroprotection
Main Article Content
Abstract
The article presents the utility of vinpocetine in neurology in chronic cerebral circulation insufficiency. The neuroprotective aspect of vinpocetine and multidirectional mechanism of the medicine have been shown. Furthermore, the effectiveness and safety of the medicine have been included. The emphasis has been put on the effective dose of the medicine (30 mg/day) in the process of treating chronic cerebral circulation insufficiency.
Article Details
How to Cite
Nowak, P. (2014). Vinpocetine in the treatment of chronic cerebral circulation insufficiency. Medycyna Faktow (J EBM), 7(2(23), 86-89. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2373
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Zaremba M., Postuła M.: Wielokierunkowe działanie winpocetyny i korzyści z tym związane w świetle badań eksperymentalnych i klinicznych. Medycyna Faktów 2013; 1(18).
2. Bałkowiec-Iskra E., Joniec I.: – Winpocetyna – nowe wskazania do stosowania – Przewodnik Lekarza.
3. Vinpocetine. Altern. Med. Rev. 2002; 7: 240-243.
4. Szobor A., Klein M.: Ethyl apovincaminate therapy in neurovascular diseases. Arzneimittelforschung 1976; 26: 1984-1989.
5. Tarnok K., Kiss E., Luiten P.G. et al.: Effects of Vinpocetine on mitochondrial function and neuroprotection in primary cortical neurons. Neurochem. Int. 2008; 53: 289-295.
6. Csillik B., Mihay A., Knyihar-Csillik E.: Antinociceptive effect of vinpocetine – a comprehensive survey. Ideggyogy Sz. 2010; 63: 185-192.
7. Pereira C., Agostinho P., Oliveira C.R.: Vinpocetine attenuates the metabolic dysfunction induced by amyloid betapeptides in PC12 cells. Free Radic. Res. 2000; 33: 497-506.
8. Valikovics A. [Investigation of the effect of vinpocetine on cerebral blood flow and cognitive functions]. Ideggyogy Sz. 2007; 60: 301-310.
9. Miyazaki M.: The effect of cerebral vasodilator, vinpocetine, on cerebral vascular resistance evaluated by the Doppler ultrasonic technique in patients with cerebrovascular diseases. Angiology 1995; 46: 53-58.
10. Burtsev E.M., Savkov V.S., Shprakh V.V. et al.: [10-years experience with using Cavinton in cerebrovascular disorders]. Zh. Nevropatol. Psikhiatr. Im. S.S. Korsakova 1992; 92: 56-60.
11. Gabryel B., Adamek M., Pudelko A. et al.: Piracetam and vinpocetine exert cytoprotective activity and prevent apoptosis of astrocytes in vitro in hypoxia and reoxygenation. Neurotoxicology 2002; 23: 19-31.
12. Miskolczi P., Korma K., Polgar M. et al.: Pharmacokinetics of vinpocetine and its main metabolite apovincaminic acid before and after the chronic oral administration of vinpocetine to humans. Eur. J. Drug. Metab. Pharmacokinet. 1990; 15: 1-5.
13. Szakal l.S., Boros I., Balkay L. et al.: Cerebral effects of a single dose of intravenous vinpocetine in chronic stroke patients: A PET study. J. Neuroimaging. 1998; 8: 197-204.
2. Bałkowiec-Iskra E., Joniec I.: – Winpocetyna – nowe wskazania do stosowania – Przewodnik Lekarza.
3. Vinpocetine. Altern. Med. Rev. 2002; 7: 240-243.
4. Szobor A., Klein M.: Ethyl apovincaminate therapy in neurovascular diseases. Arzneimittelforschung 1976; 26: 1984-1989.
5. Tarnok K., Kiss E., Luiten P.G. et al.: Effects of Vinpocetine on mitochondrial function and neuroprotection in primary cortical neurons. Neurochem. Int. 2008; 53: 289-295.
6. Csillik B., Mihay A., Knyihar-Csillik E.: Antinociceptive effect of vinpocetine – a comprehensive survey. Ideggyogy Sz. 2010; 63: 185-192.
7. Pereira C., Agostinho P., Oliveira C.R.: Vinpocetine attenuates the metabolic dysfunction induced by amyloid betapeptides in PC12 cells. Free Radic. Res. 2000; 33: 497-506.
8. Valikovics A. [Investigation of the effect of vinpocetine on cerebral blood flow and cognitive functions]. Ideggyogy Sz. 2007; 60: 301-310.
9. Miyazaki M.: The effect of cerebral vasodilator, vinpocetine, on cerebral vascular resistance evaluated by the Doppler ultrasonic technique in patients with cerebrovascular diseases. Angiology 1995; 46: 53-58.
10. Burtsev E.M., Savkov V.S., Shprakh V.V. et al.: [10-years experience with using Cavinton in cerebrovascular disorders]. Zh. Nevropatol. Psikhiatr. Im. S.S. Korsakova 1992; 92: 56-60.
11. Gabryel B., Adamek M., Pudelko A. et al.: Piracetam and vinpocetine exert cytoprotective activity and prevent apoptosis of astrocytes in vitro in hypoxia and reoxygenation. Neurotoxicology 2002; 23: 19-31.
12. Miskolczi P., Korma K., Polgar M. et al.: Pharmacokinetics of vinpocetine and its main metabolite apovincaminic acid before and after the chronic oral administration of vinpocetine to humans. Eur. J. Drug. Metab. Pharmacokinet. 1990; 15: 1-5.
13. Szakal l.S., Boros I., Balkay L. et al.: Cerebral effects of a single dose of intravenous vinpocetine in chronic stroke patients: A PET study. J. Neuroimaging. 1998; 8: 197-204.